ProPublica
Donate
New Search

Praluent

Not sure if this is your drug?
Check if your packaging has a number that matches one of the National Drug Code(s) listed below. If you do not have a number that matches, you can also look at the images of the label on DailyMed. Or search for more options.

7 manufacturing facilities

We found 4 facilities that may have manufactured this drug, as well as 3 facilities that we believe manufactured ingredients in this drug. Sometimes there are multiple facilities involved in producing a prescription drug. Information on your drug label might hold clues about which facility to examine closer. Click on a facility to get its full FDA inspection history.
Manufacturer
Sanofi Pasteur Inc.
Swiftwater, PA, United States
Last FDA Action: Aug 2, 2024
An inspector documented issues at the facility in the last inspection.
Sanofi-aventis Deutschland Gmbh
Frankfurt am Main, Germany
Last FDA Action: Jan 16, 2025
An inspector documented issues at the facility in the last inspection.
Sanofi Winthrop Industrie
Le Trait, France
Last FDA Action: Apr 25, 2023
An inspector documented issues at the facility in the last inspection.
Genzyme Ireland Limited
Waterford, Ireland
Last FDA Action: Jan 17, 2025
An inspector documented issues at the facility in the last inspection.
Ingredient Manufacturer
Regeneron Pharmaceuticals, Inc.
Rensselaer, (NY), United States
Last FDA Action: Mar 22, 2024
An inspector documented issues at the facility in the last inspection.
Sanofi Winthrop Industrie
Vitry sur-Seine, France
Last FDA Action: May 12, 2023
The FDA found issues but determined the facility can correct them voluntarily in the last inspection.
Regeneron Ireland Designated Activity Company
LIMERICK, Ireland
Last FDA Action: Mar 14, 2023
An inspector documented issues at the facility in the last inspection.

Frequently Asked Questions

What Do the Inspection Outcomes Mean?
These are the possible FDA compliance outcomes we highlight:
  • Import alert. This is rare and means drugs from this facility were banned from coming into the U.S. Specifically we are including alerts relating to FDA manufacturing standards for drug products. The agency sometimes exempts certain drugs from import bans, ostensibly to prevent drug shortages.
  • Warning letter. This is a disciplinary tool the FDA uses to lay out significant violations of federal requirements. The company has an opportunity to respond and/or provide its plans to correct the issues. The agency might later issue a “close-out letter” to say it has confirmed that issues raised in a previous warning letter were fixed. But that doesn’t always happen.
  • Unacceptable state of compliance. This means inspectors found serious issues at the facility and the agency ultimately recommended official compliance action. In cases like this, the FDA typically pauses the facility’s pending drug approvals. The agency classifies this as “official action indicated.”
  • Some issues found, but no further FDA action. This is very common. It means the FDA found issues but determined the facility can correct them voluntarily. In some cases, inspectors may have recommended a different (potentially more serious) classification, but the agency declined to pursue further enforcement at the time. The agency classifies this as “voluntary action indicated.”
  • Inspector documented issues. Inspectors can file notes summarizing deficiencies observed during an inspection using a 483 form. In some cases, we’re unable to connect a Form 483 to an FDA inspection designation, but we show that an inspector filed this form, perhaps as part of an inspection that was not included in the public inspection dashboard.
  • Acceptable state. This is common and the best possible outcome for an inspection. This means the FDA took no compliance action and ProPublica found no issues documented by inspectors. That doesn’t always mean no issues turned up. Sometimes, inspectors address concerns with management on site that they believe do not need to be documented on a 483. The agency classifies this as “no action indicated.”
There may be additional communications, including about issues being resolved, that are not reflected in our database because they have not been made public.

How Did ProPublica Connect This Information?
We have written an in-depth methodology, but in short, we connected several FDA databases:
  • The Structured Product Labeling database.
  • The National Drug Code Directory.
  • The Electronic Drug Registration and Listing System.
  • Data from the agency’s inspection dashboard.
  • A spreadsheet of facility addresses we sued the FDA for, which connected them to drug application numbers.
  • Form 483 documents we received from a Freedom of Information Act Request.
ProPublica described the app and the methodology used to build it to the FDA, which did not comment. The agency previously told ProPublica that it doesn’t reveal where drugs are made on inspection reports to protect what it deemed confidential commercial information.

How Do I Report Incorrect Information?
If you work for a manufacturer or otherwise see that information we are displaying may be incorrect, please email [email protected].